These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11349746)

  • 1. Poor adherence with hypolipidemic drugs: a lost opportunity.
    Tsuyuki RT; Bungard TJ
    Pharmacotherapy; 2001 May; 21(5):576-82. PubMed ID: 11349746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Needed: pragmatic clinical trials for statin-intolerant patients.
    Maningat P; Breslow JL
    N Engl J Med; 2011 Dec; 365(24):2250-1. PubMed ID: 22085320
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
    Ginsberg HN
    Clin Cardiol; 1995 Jun; 18(6):307-15. PubMed ID: 7664504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review.
    Murali KM; Mullan J; Chen JH; Roodenrys S; Lonergan M
    BMC Nephrol; 2017 Jan; 18(1):42. PubMed ID: 28143438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of use of lipid-lowering medications: a cross-national study.
    Avorn J; Monette J; Lacour A; Bohn RL; Monane M; Mogun H; LeLorier J
    JAMA; 1998 May; 279(18):1458-62. PubMed ID: 9600480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
    Stefanutti C; Morozzi C; Di Giacomo S
    Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of clinical outcome studies among cholesterol-lowering agents.
    Lousberg TR; Denham AM; Rasmussen JR
    Ann Pharmacother; 2001 Dec; 35(12):1599-607. PubMed ID: 11793629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Enduracin--a nicotinic acid preparation in the treatment of hypercholesterolemia].
    Kardiologiia; 1993; 33(11):67-80. PubMed ID: 8145429
    [No Abstract]   [Full Text] [Related]  

  • 10. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 11. Economics of lipid lowering with HMG CoA reductase inhibitors.
    Illingworth DR
    Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.
    Goldie C; Taylor AJ; Nguyen P; McCoy C; Zhao XQ; Preiss D
    Heart; 2016 Feb; 102(3):198-203. PubMed ID: 26370223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of high blood cholesterol in patients with coronary heart disease].
    Nagai Y; Yanagi K; Yamashita S; Takemura K; Matsuzawa Y
    Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):1088-94. PubMed ID: 12436661
    [No Abstract]   [Full Text] [Related]  

  • 15. Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention?
    Green L
    Fam Pract; 1997 Oct; 14(5):411-5. PubMed ID: 9472378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 17. [In process].
    Reisdorf S
    Med Monatsschr Pharm; 2017 Jun; 40(6):271-3. PubMed ID: 29979855
    [No Abstract]   [Full Text] [Related]  

  • 18. Beyond statins: lipid management to reduce cardiovascular risk.
    Schuck RN; Mendys PM; Simpson RJ
    Pharmacotherapy; 2013 Jul; 33(7):754-64. PubMed ID: 23606278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes.
    Pladevall M; Williams LK; Potts LA; Divine G; Xi H; Lafata JE
    Diabetes Care; 2004 Dec; 27(12):2800-5. PubMed ID: 15562188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.